PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

BRAF inhibitors (BRAFi) selectively target oncogenic BRAF(V600E/K) and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better characterization of the underlying molecular proce...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Vidarsdottir, Linda, Azimi, Alireza, Das, Ishani, Sigvaldadottir, Ingibjorg, Suryo Rahmanto, Aldwin, Petri, Andreas, Kauppinen, Sakari, Ingvar, Christian, Jönsson, Göran, Olsson, Håkan, Frostvik Stolt, Marianne, Tuominen, Rainer, Sangfelt, Olle, Pokrovskaja Tamm, Katja, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Johnsson, Per
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8155038/
https://ncbi.nlm.nih.gov/pubmed/34040017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-89389-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados